NeoGenomics Inc. (NASDAQ: NEO) reported first‑quarter 2026 revenue of $186.7 million, an 11% year‑over‑year increase, and a net loss of $17.1 million, a 34% improvement from the $26 million loss reported in Q1 2025. The company’s adjusted earnings before interest, taxes, depreciation and amortization rose 27% to $9.0 million, reflecting stronger operating leverage.
The quarter’s top‑line growth was driven by a 14% rise in clinical revenue, largely fueled by a 26% increase in next‑generation sequencing (NGS) testing volumes. The full clinical launch of the RaDaR® ST minimal residual disease (MRD) assay in February added a new high‑margin product line, while the PanTracer portfolio continued to expand.
NeoGenomics raised its full‑year 2026 revenue guidance to $797 million–$803 million, up from the $793 million–$801 million range issued in February. Adjusted EBITDA guidance for the year remains in the 27%–31% range, unchanged from the prior outlook. The company’s confidence in sustained demand is underscored by the guidance revision.
Revenue mix analysis shows that clinical services accounted for the majority of the increase, whereas non‑clinical revenue declined 15% due to softness in the pharmaceutical sector. NGS testing, a core growth engine, contributed a 26% volume lift, while the new RaDaR® ST assay added a significant margin premium.
Margin dynamics reveal that adjusted gross margin contracted 80 basis points to 46% because of dilution from the Pathline acquisition and the early launch of PanTracer Liquid before MolDX approval. However, higher average unit prices and laboratory efficiency gains partially offset these headwinds. Adjusted EBITDA margin expanded 60 basis points, driven by operating leverage in general and administrative expenses.
Management highlighted the company’s “transformational” quarter, noting that the RaDaR® ST launch represents a “$20 billion addressable market that is underpenetrated and growing rapidly.” CFO Abhishek Jain added that the company expects gross margin expansion of approximately 100 basis points for the full year, citing the “Lab of the Future” initiatives.
Investors focused on margin compression and the decline in non‑clinical revenue, while also weighing the company’s strong NGS and MRD performance. The market reaction was muted, reflecting concerns about short‑term margin pressure despite the revenue beat and guidance upgrade.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.